AbCellera is actively transitioning from a partner-only antibody discovery service model to a clinical-stage biotechnology company developing its own proprietary drug pipeline. The company aims to introduce at least two molecules to the clinic annually.

Expected impact: Shifts the business model toward capturing higher-value downstream stakes, milestones, and royalties from wholly-owned assets, reducing reliance on lumpy fee-for-service revenues.

Operationalizing the newly completed 130,000-square-foot clinical manufacturing facility in Vancouver to produce GMP clinical batches.

Expected impact: Enhances vertical integration, provides complete control over the clinical supply chain, accelerates pipeline timelines, and protects proprietary intellectual property.